Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | MABCUTE: rituximab maintenance in R/R indolent NHL

Simon Rule • 14 Jun 2019
EHA 2019
Lymphoma Mantle Cell Lymphoma Rituximab
MABCUTE

Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the results of the phase III MABCUTE study (NCT01461928) which investigated the efficacy and safety of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-hodgkin lymphoma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Simon Rule

0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals